Resultados de la búsqueda - Portal de Modelos de Datos Médicos (MDM-Portal)

UKHD - Universitäts-Frauenklinik, Sektion Senologie Verlaufsblatt - Mamma Carcinom - Verlaufsangaben

- 9/3/22 - 10 formularios, 3 itemgroups, 38 items, 1 idioma

Itemgroups: Verlaufsangaben, Präoperative Vorbereitung - Checkliste, OP und Verlauf

Routinedokumentation der Universitäts-Frauenklinik, Sektion Senologie Verlaufsblatt - Mamma Carcinom - Multimodale Brustdiagnostik. Sektionsleiter Senologie: Prof. Dr. med. Jörg Heil, MHBA

Empfehlung des postoperativen Tumorboards

1 itemgroup 26 items

Prätherapeutische und präoperative Konferenz(en)

5 itemgroups 46 items

Allgemeines: Personalien, Diagnose, Therapie und Anamnese

3 itemgroups 43 items

Present aftercare Physician’s questionnaire for aftercare ABC study - Present aftercare Physician’s questionnaire for aftercare

- 20/9/21 - 1 formulario, 11 itemgroups, 99 items, 1 idioma

Itemgroups: Administrative, Medical Examination, Medical consultation, laboratory tests, Aftercare, medical consultation early cancer prevention, vaccination status, cardiovascular risk factor, Rehabilitation measures, Physical therapy, Medication

Study part: Present aftercare Physician’s questionnaire for aftercare ABC Study. Aftercare pattern in adult patients with blood cancer and blood cancer early stage: Impact on health related endpoints, quality of life and health resource use. University clinic essen, (Klinik für Hämatologie Uniklinik Essen, UKE), department hematology. Permission granted by Claudia Ose.

B. Possible late effects of disease or treatment Questionnaire for aftercare ABC study - B. Possible late effects of disease or treatment Questionnaire for aftercare

- 20/9/21 - 1 formulario, 20 itemgroups, 147 items, 1 idioma

Itemgroups: Infection, Infection, Fertility, measure Fertility, Therapy; Offspring desire, Therapy; Offspring desire, Medical Examination; Fertility problem, number of children Therapy naive, number of children therapy end, Second or other cancer diagnoses, Second or other cancer diagnoses symptom First, Medical Examination Second or other cancer diagnoses, therapy Second Primary Cancers, Cardiovascular Diseases, Cardiovascular Diseases, Medical Examination Cardiovascular Diseases, Therapy Cardiovascular Diseases, Polyneuropathy, Medical Examination Polyneuropathy, Therapy Polyneuropathy

Study part: B. Possible late effects of disease or treatment Questionnaire for aftercare ABC Study. Aftercare pattern in adult patients with blood cancer and blood cancer early stage: Impact on health related endpoints, quality of life and health resource use. University clinic essen, (Klinik für Hämatologie Uniklinik Essen, UKE), department hematology. Permission granted by Claudia Ose.

C. General health care and medical check-ups Questionnaire for aftercare ABC study - C. General health care and medical check-ups Questionnaire for aftercare

- 20/9/21 - 1 formulario, 6 itemgroups, 45 items, 1 idioma

Itemgroups: Health Care, Medical Examination Screening for cancer, Precaution cardiovascular diseases, Medical Examination Complication Diabetes Mellitus, Medical Examination Complication Hypertension, Vaccinations

Study part: C. General health care and medical check-ups Questionnaire for aftercare ABC Study. Aftercare pattern in adult patients with blood cancer and blood cancer early stage: Impact on health related endpoints, quality of life and health resource use. University clinic essen, (Klinik für Hämatologie Uniklinik Essen, UKE), department hematology. Permission granted by Claudia Ose.

Efficacy of P. Falciparum Vaccine Against Malaria in Children NCT00380393 - Active Case Detection

- 10/8/21 - 1 formulario, 4 itemgroups, 15 items, 1 idioma

Itemgroups: Administrative, Active Case Detection Malaria, Treated Bed Net, Indoor Residual Spray

Study ID: 106464 Clinical Study ID: 106464 Study Title: A Study of the Efficacy Against Episodes of Clinical Malaria Due to P. Falciparum Infection of GSK Biologicals Candidate Vaccine RTS, S/AS01, Administered According to a 0,1,2-months Schedule in Children Aged 5 to 17 Months Living in Tanzania & Kenya Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00380393 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 2 Study Recruitment Status: Completed Generic Name: GSK malaria vaccine 257049 Vaccine, Sanofi-Pasteur's Human Diploid Cell Rabies Vaccine Trade Name: N/A Study Indication: Malaria ODM derived from https://clinicaltrials.gov/ct2/show/study/NCT00380393. This Phase IIb randomized, double-blind, controlled study of the efficacy against episodes of clinical malaria due to Plasmodium falciparum infection of GlaxoSmithKline Biologicals’ candidate vaccine RTS, S/AS01E, administered IM according to a 0, 1, 2-month vaccination schedule in children aged 5 months to 17 months living in Tanzania and Kenya. This study includes the following 7 clinical study visits (3 different visit types) during a double-blind phase (Day -60 to Month 6 1/2) and a single-blind phase including an extension for a subset of patients (month 7 to month 14). Clinical visit 1: Baseline visit, screening, and randomisation (DAY -60 to 0) Clinical visit 2: Vaccination I (MONTH 0, DAY 0 | DOSE 1 | 0 - 60 DAYS AFTER VISIT 1) Clinical visit 3: Vaccination II (MONTH 1, DAY 30 | DOSE 2 | 21 - 35 DAYS AFTER VISIT 2) Clinical visit 4: Vaccination III (MONTH 2, DAY 60 | DOSE 3 | 21 - 35 DAYS AFTER VISIT 3) Clinical visit 5: Blood Sample, ACD (MONTH 3, DAY 90 | 21 - 42 DAYS AFTER VISIT 4) Clinical visit 6: Blood Sample, ACD (MONTH 6 1/2 | CROSS-SECTIONAL VISIT FOR ACD | FINAL STUDY VISIT FOR DOUBLE-BLIND PHASE) Clinical visit 7: Blood Sample, ACD (MONTH 14 | FINAL STUDY VISIT SINGLE-BLIND PHASE) Field-worker home visits: During the vaccination period, clinical visits are accompanied by daily field-worker visits for a one-week period subsequent to each vaccine administration at clinical visits 2, 3, and 4 (visit code 21-26 following clinical visit 2; visit code 27-32 following clinical visit 3; visit code 33-38 following clinical visit 4). After completion of the vaccination period, clinical visits are then accompanied by weekly field-worker home visits (visit code 39-40 following clinical visit 4/dose 3; visit code 41-55 following clinical visit 5; visit code 56-86 following clinical visit 6). These visits serve the additional purpose of Active Case Detection (ACD). Passive Case Detection (PCD) for clinical malaria disease is performed both during the course of the double-blind (day -60 to month 6 1/2) and the single-blind phase (month 7 to month 14). This form should be filled in at every field-worker home visit as well as at clinical visit 5, 6, and 7. For field-worker home visits No° 55 and No° 86, please complete the additional questions as indicated in the form. Note that informed consent has to be obtained prior to any study procedure.

Efficacy of P. Falciparum Vaccine Against Malaria in Children NCT00380393 - Passive Case Detection

- 10/8/21 - 1 formulario, 2 itemgroups, 12 items, 1 idioma

Itemgroups: Administrative, Passive Case Detection Malaria

Study ID: 106464 Clinical Study ID: 106464 Study Title: A Study of the Efficacy Against Episodes of Clinical Malaria Due to P. Falciparum Infection of GSK Biologicals Candidate Vaccine RTS, S/AS01, Administered According to a 0,1,2-months Schedule in Children Aged 5 to 17 Months Living in Tanzania & Kenya Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00380393 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 2 Study Recruitment Status: Completed Generic Name: GSK malaria vaccine 257049 Vaccine, Sanofi-Pasteur's Human Diploid Cell Rabies Vaccine Trade Name: N/A Study Indication: Malaria ODM derived from https://clinicaltrials.gov/ct2/show/study/NCT00380393. This Phase IIb randomized, double-blind, controlled study of the efficacy against episodes of clinical malaria due to Plasmodium falciparum infection of GlaxoSmithKline Biologicals’ candidate vaccine RTS, S/AS01E, administered IM according to a 0, 1, 2-month vaccination schedule in children aged 5 months to 17 months living in Tanzania and Kenya. This study includes the following 7 clinical study visits (3 different visit types) during a double-blind phase (Day -60 to Month 6 1/2) and a single-blind phase including an extension for a subset of patients (month 7 to month 14). Clinical visit 1: Baseline visit, screening, and randomisation (DAY -60 to 0) Clinical visit 2: Vaccination I (MONTH 0, DAY 0 | DOSE 1 | 0 - 60 DAYS AFTER VISIT 1) Clinical visit 3: Vaccination II (MONTH 1, DAY 30 | DOSE 2 | 21 - 35 DAYS AFTER VISIT 2) Clinical visit 4: Vaccination III (MONTH 2, DAY 60 | DOSE 3 | 21 - 35 DAYS AFTER VISIT 3) Clinical visit 5: Blood Sample, ACD (MONTH 3, DAY 90 | 21 - 42 DAYS AFTER VISIT 4) Clinical visit 6: Blood Sample, ACD (MONTH 6 1/2 | CROSS-SECTIONAL VISIT FOR ACD | FINAL STUDY VISIT FOR DOUBLE-BLIND PHASE) Clinical visit 7: Blood Sample, ACD (MONTH 14 | FINAL STUDY VISIT SINGLE-BLIND PHASE) Field-worker home visits: During the vaccination period, clinical visits are accompanied by daily field-worker visits for a one-week period subsequent to each vaccine administration at clinical visits 2, 3, and 4 (visit code 21-26 following clinical visit 2; visit code 27-32 following clinical visit 3; visit code 33-38 following clinical visit 4). After completion of the vaccination period, clinical visits are then accompanied by weekly field-worker home visits (visit code 39-40 following clinical visit 4/dose 3; visit code 41-55 following clinical visit 5; visit code 56-86 following clinical visit 6). These visits serve the additional purpose of Active Case Detection (ACD). Passive Case Detection (PCD) for clinical malaria disease is performed both during the course of the double-blind (day -60 to month 6 1/2) and the single-blind phase (month 7 to month 14). This document should be completed whenever unscheduled visits for passive case detection take place. Note that informed consent has to be obtained prior to any study procedure.

aftercare status prostate cancer - HIS

- 15/3/21 - 1 formulario, 6 itemgroups, 62 items, 2 idiomas

Itemgroups: Patientenaufkleber groß, Anamnese, PSA, Kontinenz, Potenz, Nebentherapie

HIS form ORBIS. with friendly permission form urology (Prof. Semjonow) and medical informatics department (Dr. Breil)

7% CO2, GW597599, paroxetine andor alprazolam in healthy volunteers 100690 - Follow-Up

- 23/10/17 - 1 formulario, 4 itemgroups, 11 items, 1 idioma

Itemgroups: Administrative Documentation, Urine Pregnancy Test, Clinical Chemistry and Haematology, Urinalysis

Study ID: 100690 Clinical Study ID: NKP100690 Study Title: A randomised, double blind triple dummy, placebo controlled balanced incomplete block crossover study to evaluate the change in response to a 7% CO2 challenge and pharmacokinetics of single oral doses of GW597599 and paroxetine (5 or 7.5 mg) either alone or in combination, or alprazolam (0.75 mg) in healthy volunteers Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: Sponsor: GlaxoSmithKline Collaborators: N/A Phase: phase 1 Study Recruitment Status: Completed Generic Name: paroxetine Trade Name: Tagonis,Seroxat,Paxil,Paroxat,Deroxat,Aropax Study Indication: Depressive Disorder and Anxiety Disorders CRF Seiten: 255-365

7% CO2, GW597599, paroxetine andor alprazolam in healthy volunteers 100690 - Follow-Up Unscheduled

- 23/10/17 - 1 formulario, 3 itemgroups, 7 items, 1 idioma

Itemgroups: Administrative Documentation, Clinical Chemistry and Haematology, Urinalysis

Study ID: 100690 Clinical Study ID: NKP100690 Study Title: A randomised, double blind triple dummy, placebo controlled balanced incomplete block crossover study to evaluate the change in response to a 7% CO2 challenge and pharmacokinetics of single oral doses of GW597599 and paroxetine (5 or 7.5 mg) either alone or in combination, or alprazolam (0.75 mg) in healthy volunteers Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: Sponsor: GlaxoSmithKline Collaborators: N/A Phase: phase 1 Study Recruitment Status: Completed Generic Name: paroxetine Trade Name: Tagonis,Seroxat,Paxil,Paroxat,Deroxat,Aropax Study Indication: Depressive Disorder and Anxiety Disorders CRF Seiten: 255-365

POST-TREATMENT COUNT FINGERS DAY 0 CRFs Roche FVF4170G Macular Edema NCT00473382

- 9/6/17 - 1 formulario, 2 itemgroups, 12 items, 1 idioma

Itemgroups: Patient administration, POST-TREATMENT COUNT FINGERS (DAY 0)

Terms of use: You may not use this document or the information contained herein to a regulatory authority in connection with an application for a marketing authorization or any other regulatory submission without the express written consent of Roche Study #: FVF4170g Drug: Ranibizumab Study Title: A Phase III, Double-Masked, Multicenter, Randomized, Sham-Controlled Study Of The Efficacy And Safety Of Ranibizumab Injection In Subjects With Clinically Significant Macular Edema With Center Involvement Secondary To Diabetes Mellitus

POST-TREATMENT COUNT FINGERS DAY 0 CRFs Roche FVF4168G Macular Edema NCT00473330

- 9/6/17 - 1 formulario, 2 itemgroups, 12 items, 1 idioma

Itemgroups: Patient administration, POST-TREATMENT COUNT FINGERS (DAY 0)

Terms of use: You may not use this document or the information contained herein to a regulatory authority in connection with an application for a marketing authorization or any other regulatory submission without the express written consent of Roche Study #: FVF4168g Drug: Ranibizumab Study Title: A Phase III, Double-Masked, Multicenter, Randomized, Sham-Controlled Study Of The Efficacy And Safety Of Ranibizumab Injection In Subjects With Clinically Significant Macular Edema With Center Involvement Secondary To Diabetes Mellitus

Cancer follow-up treatment form, University Hospital Cologne

- 29/4/17 - 1 formulario, 3 itemgroups, 45 items, 2 idiomas

Itemgroups: Follow-up treatment for cancer patients, Physical examination finding, Comorbidity

Hospital Routine Documentation Subform at the University Hospital Cologne. Original Form name: CA_AHB-Befundbericht

Palabras clave

Tabla de contenido

Modelos de datos seleccionados